HSKA 15.90 Heska Corp $HSKA Hit a 52 week high of 16.72

New Post Public Reply Private Reply Replies (0) Message Board

Nov 7, 2014 at 11:03 PM

HSKA 15.90 Heska Corp $HSKA Hit a 52 week high of 16.72 Closing the day 11/07/14 at 15.90 +0.71 +4.67% With a day low of 15.15 and a total volume of 272,213.

HSKA Recent Posts: http://investorshangout.com/Heska-Corp-HSKA-54376/

HSKA Heska Corp Recent Headline News

Achillion Pharmaceuticals Slumps: ACHN Plunges 15.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:34AM CST
Achillion Pharmaceuticals (ACHN) fell nearly 16% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up nearly 3% in the past one month.
AGEN: 3.02 (-0.03), HSKA: 15.90 (+0.71), ACHN: 10.11 (-0.15), AMAG: 34.95 (+0.83)

Heska Announces Investor Day in New York City
PR Newswire - Tue Nov 04, 8:00AM CST
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today announced the Company will conduct an Investor Day, from 9 a.m. to noon (EST) on Friday, November 14, 2014. The event will be at the Nasdaq MarketSite in Times Square, located at One Liberty Plaza, 165 Broadway, in New York City.
HSKA: 15.90 (+0.71)

Qiagen Q3 Earnings, Revenues in Line; Outlook Revised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 1:50PM CDT
Qiagen's (QGEN) strategic collaborations, test menu expansions and moderately balanced international expansion will likely drive growth over time.
BIIB: 320.75 (-2.72), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52), QGEN: 23.48 (-0.20)

Can the Rally in Heska (HSKA) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:06AM CDT
Can the Rally in Heska (HSKA) Shares Continue?
HSKA: 15.90 (+0.71)

Heska Reports 24% Revenue Growth, $0.08 Per Share for the Third Quarter of 2014
PR Newswire - Wed Oct 29, 8:00AM CDT
Heska Corporation (NASDAQ: HSKA; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, today reported financial results for its third quarter ended September 30, 2014.
HSKA: 15.90 (+0.71)

Heska Signs Distribution Agreement with Henry Schein Animal Health
PR Newswire - Wed Oct 29, 7:45AM CDT
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"

, a provider of advanced veterinary diagnostic and other specialty veterinary products, announced today a new distribution agreement with Henry Schein Animal Health, the largest companion animal health distribution company in the U.S. Henry Schein Animal Health will market and promote Heska's full line of hematology and chemistry instruments and affiliated consumables, effective immediately.
HSKA: 15.90 (+0.71), HSIC: 128.84 (-1.47)

Webcast Alert: Heska Announces Third Quarter 2014 Earnings Conference Call Webcast
PR Newswire - Tue Oct 28, 3:30PM CDT
Heska Corporation (Nasdaq: HSKA) announces the following Webcast:
HSKA: 15.90 (+0.71)

Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:46AM CDT
Repros Therapeutics (RPRX) was a big mover last session, with shares surging almost 17% on the day.
CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), RPRX: 10.12 (+3.67)

Cyclacel Pharmaceuticals (CYCC) in Focus: Stock Jumps 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 29, 8:21AM CDT
Cyclacel Pharmaceuticals, Inc. (CYCC) was a big mover last session, as the company saw its shares rise by over 5% on the day.
HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), CYCC: 3.09 (-0.06), GILD: 106.45 (-0.49)

Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 2:20PM CDT
Currently, Myriad Genetics (MYGN) is financing 13 Phase III clinical trials with flagship product BracAnalysis CDx in six different indicated patient populations.
MYGN: 34.89 (+0.11), HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), GILD: 106.45 (-0.49)

Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 1:50PM CDT
On Sep 25, we issued an updated research report on Qiagen N.V. (QGEN).
HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), ANTH: 1.84 (-0.02), QGEN: 23.48 (-0.20)

Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 8:25AM CDT
Rexahn Pharmaceuticals (RNN) was a big mover last session, as the company saw its shares rise over 10% on the day.
RNN: 0.71 (+0.01), HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), GILD: 106.45 (-0.49)

Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:46AM CDT
Dynavax (DVAX) was a big mover last session, with shares rising nearly 7% on the day.
DVAX: 1.59 (unch), HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), ILMN: 186.35 (-3.52)

Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 7:44AM CDT
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as the company saw its shares rise over 5% on the day.
ALDR: 16.57 (-0.25), CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52)

Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 2:30PM CDT
On Sep 16, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN).
HSKA: 15.90 (+0.71), GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), ILMN: 186.35 (-3.52)

Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:44AM CDT
Dendreon Corp. (DNDN) was a big mover last session, as the company saw its shares rise over 9% on the day
CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), DNDN: 0.94 (+0.11), ILMN: 186.35 (-3.52)

Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 7:44AM CDT
Cytokinetics (CYTK) as a big mover last session, as the company saw its shares surge over 17 % on the day
CYTK: 4.10 (-0.15), CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52)

Synthetic Biologics (SYN) Looks Strong: Stock Gains 13.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 7:44AM CDT
Synthetic Biologics (SYN) was a big mover last session, as the company saw its shares gain nearly 14% on the day
SYN: 1.49 (+0.07), CBM: 22.66 (-0.82), HSKA: 15.90 (+0.71), ILMN: 186.35 (-3.52)

China Biologic Products, Inc. (CBPO) Rises: Stock Jumps 7.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 8:32AM CDT
China Biologic Products, Inc. (CBPO) was a big mover last session, as the company saw its shares rise more than 7% on the day.
CBPO: 68.90 (-0.08), HSKA: 15.90 (+0.71), CBM: 22.66 (-0.82), GILD: 106.45 (-0.49)

Heska Corp. (HSKA) Stock Research Links

HSKA Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rural Hospitals Face Shaky Future; Warbird RCM Steps In

Revamping Revenue Cycle Management for Rural Healthcare In a world that's increasingly teetering on the delicate tightrope of balance sheets, Warbird Healthcare Advisors is stepping into the ring with fists up, ready to fight for rural hospitals. Introducing their latest venture, Warbird RCM Partners, they're honing in on revenue cycle management and billing services to...

When Families Should Consider Life Insurance Plans

Let’s talk about why life insurance isn’t just for those walking around with gray hair. K.D. the Insurance Queen from Centennial, Colorado, dishes out the clearest advice on when and why families ought to have it in their arsenal. A New Mindset on Life Insurance Some folks out there think life insurance is something you ponder in your twilight years. But here’s the...

Critical Questions to Ask When Buying Life Insurance

Getting Under the Hood of Life Insurance Alright, so you're thinking about life insurance. Not exactly a day at the beach, but it’s one of those crucial life things to nail down. Paula Miller, a savvy insurance pro, walks through what to consider before you just slap down a signature and hope for the best. The Basics: Policy Types and Coverage Life insurance can be as...

Centrus Energy to Discuss Q3 Earnings on Nov 5 Call

Centrus Energy Prepares for Earnings Call You ever feel that twinge in your gut right before a big disclosure? Well, that's where Centrus Energy’s about to take us as they gear up for their quarterly earnings call. On November 5th, bright and early at 8:30 a.m. Eastern Time, NYSE:LEU will be in the spotlight, laying out its Q3 results for all us nose-to-the-grindstone...

Ellington's Q3 Earnings Call: What Investors Need to Know

An Anticipated Unveiling Ellington Financial Inc. (NYSE:EFC) is gearing up to spill the beans on its third-quarter financials for 2026. It's all going down after the markets close on November 4th. I can tell you, folks, anyone keeping an eye on EFC will be itching to know what's inside those numbers. With a company this deep into financial assets, reading between the...

Podium Surges Past $150M in AI ARR Milestone

A New Era for Podium When the brass at Podium made a gamble on AI, they didn't just try squeezing it into their old business model. Oh no, they launched what feels like a startup within their existing empire—no half-measures, just full-throttle ambition. Fast forward two and a half years, and they've racked up over $150 million in annual recurring revenue from these...

Harbour BioMed's Batoclimab Injected Into Myasthenia Market

China's Green Light for Batoclimab When a new drug approval hits, particularly in a crucial market like China, it's a big deal. Harbour BioMed's recent go-ahead from the National Medical Products Administration (NMPA) for their Batoclimab injection is no exception. This marks the first full clinical cycle completion of an anti-FcRn treatment for generalized myasthenia...

Gillis Joins McGinnis Lochridge as COO Amid Firm's Milestone

An Experienced Executor at the Helm Now, here's a story that rings of continuity meeting change. McGinnis Lochridge, a staple of the Texas legal scene since 1927, has tapped Charles Gillis to take charge as their Chief Operating Officer. You'd think they're gearing up to celebrate a hundred years by shaking things up internally. Why not bring in someone seasoned, I say?...

Dott's Q3 2026: Micromobility Growth Soars High

Riding the Wave of Profit in Micromobility Sometimes all you need is a quick jolt of genius to turn the wheels of fortune. Dott seems to have hit that sweet spot in Q3 of 2026. Deploying 45,000 new vehicles wasn’t just a logistical feat; it was a calculated bet that paid off handsomely, bolstering their business to soaring heights. Performance that Packs a Punch The Q3...

NYC's Carriage Horse Ban: A New Era for Urban Welfare

You've got to hand it to New York City—this isn't just another Tuesday twist. The City Council's decision to nix horse-drawn carriages is like throwing a wrench in an antique machine. It's a bold move in a concrete jungle that's constantly wearing new coats. Tradition vs. Welfare: The Crux For years, the idea of horses prancing down NYC streets seemed like a quaint nod...